Here are 18 points of comparison from Medtronic, Johnson & Johnson, Stryker, Zimmer Biomet, Smith+Nephew and NuVasive.
Medtronic (fourth quarter of the FY)
1. Revenue: $6 billion (26 percent decline)
2. Restorative therapy group, including spine, revenue: $7.725 billion (5.6 percent decline)
3. Spine revenue: $480 million (31 percent decline)
Johnson & Johnson Orthopedics
1. Sales: $2 billion (7.5 percent decline)
2. Trauma sales: $654 million (4.5 percent decline)
3. Spine, sports and other: $703 million (10 percent decline)
Stryker
1. Net sales: $3.6 billion (2 percent increase)
2. Orthopedic sales: $1.2 billion (2.1 percent decline)
3. Spine and nanotechnology sales: $700 million (0.7 percent increase)
Zimmer Biomet
1. Net sales: $1.78 billion (9.7 percent decline)
2. Net loss: $509 million
3. Spine, Dental, craniomaxillofacial revenue: $252 million (12.4 percent decline)
Smith+Nephew
1. Revenue: $1.1 billion (7.6 percent decline)
2. Orthopedic revenue: $497 million (9 percent decline)
3. Sports medicine and ENT revenue: $328 million (11 percent decline)
NuVasive
1. Revenue: $259.9 million (5.4 percent decline)
2. Net income: $5.3 million (43.6 percent decline)
3. The company made executive compensation cuts and pulled back on discretionary spending due to the pandemic.
More articles on devices:
Medtronic’s pipeline includes spine, robotics innovations despite pandemic setbacks
3 spine, neurosurgery device recalls in the past year
Aetna to cover sacroiliac joint fusion under new policy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.